New Posts New Posts RSS Feed - Any BRCA neg done carboplatin taxane after ACT?
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Any BRCA neg done carboplatin taxane after ACT?

 Post Reply Post Reply
Author
mkcrowe View Drop Down
Newbie
Newbie
Avatar

Joined: Apr 27 2016
Location: San Francisco
Status: Offline
Points: 11
Post Options Post Options   Thanks (0) Thanks(0)   Quote mkcrowe Quote  Post ReplyReply Direct Link To This Post Topic: Any BRCA neg done carboplatin taxane after ACT?
    Posted: Apr 27 2016 at 3:46pm
Hi,

I have a recurrence (small tumor, four years out, NED). I did ACT first time around, and my recommended tx option is carboplatin taxane combo. I am BRCA negative and this is shown to have less benefit.

Anyone else with BRCA negative who had to find a second line of defense? What was it? What did you learn? How did it go?

I tried posting earlier but thought this newly phrased posting might elicit more response.

THANK YOU!
Back to Top
Beattnbc2016 View Drop Down
Newbie
Newbie
Avatar

Joined: Apr 21 2016
Location: Maryland
Status: Offline
Points: 8
Post Options Post Options   Thanks (0) Thanks(0)   Quote Beattnbc2016 Quote  Post ReplyReply Direct Link To This Post Posted: Apr 27 2016 at 11:23pm
Hi,

Unfortunately both my sister and i are BRCA Pos.  I took carboplatin after a clinical trial "G" drug with Taxol, AC followed by carboplatin.  My sister currently taking carboplatin and taxane for ovarian cancer (TNBC survivor) with promising results. Have you talked to your doctor about benefits of a clinical trial? PD1 has had very promising results for different types of cancers, now there's a trial for Triple Negative. There is a phase 1 & 2 trial I believe.  Wish you the best.  

Tee


Dx 3/26/2015, TN,Brca1+, Trial+Taxol,AC,Double Mastectomy,Carbonplatin,Oferectomy, Reconstruction
Back to Top
caregiver20 View Drop Down
Newbie
Newbie


Joined: May 10 2016
Status: Offline
Points: 32
Post Options Post Options   Thanks (1) Thanks(1)   Quote caregiver20 Quote  Post ReplyReply Direct Link To This Post Posted: May 10 2016 at 11:02am
Hey, my wife is BRCA- and had the carboplatin-taxotere combination as an adjuvant therapy following her initial ACT and mastectomy but before radiation. They weren't able to see the results, as the primary tumor had already been removed, but she had a recurrence shortly after the radiation finished, so the assumption was that it wasn't helpful. The side effects were fairly tolerable, in comparison with the ACT, but I think I would question the usefulness (at the time we didn't realize that platinum treatments are more effective with BRCA+). To me it's especially illogical to do if you've already received taxol, which she had (but I'm not an expert!). 
Back to Top
mkcrowe View Drop Down
Newbie
Newbie
Avatar

Joined: Apr 27 2016
Location: San Francisco
Status: Offline
Points: 11
Post Options Post Options   Thanks (0) Thanks(0)   Quote mkcrowe Quote  Post ReplyReply Direct Link To This Post Posted: May 10 2016 at 11:52am
Thank you for your reply. And I am so sorry it didn't work. This is my fear too- that for BRCA- it won't work, although it's good to hear the affects weren't as bad as ACT because that was really rough. I am so sorry you all had to go through that again, and I really appreciate your response.

Kelsey
Back to Top
gordon15 View Drop Down
Senior Member
Senior Member


Joined: Jun 22 2015
Location: San Diego CA
Status: Offline
Points: 788
Post Options Post Options   Thanks (0) Thanks(0)   Quote gordon15 Quote  Post ReplyReply Direct Link To This Post Posted: May 10 2016 at 12:23pm
My wife had Carbo/Gem chemo before surgery, it reduced tumor from 5cm to 1.2cm and killed cancer in 4 lymph nodes (pCR) she is BRCA- and neg for another 5 genes they tested for(AmbreyGenomics) and  found out androgen negative also.
 
She couldn't have AC on 2015 diagnosis b/c she had it in 2008 and would exceed limit for Adrymycin ("A), and having squamous features, Carbo/Gem was recommd.
 She had Taxol after surgery.

 PET/CT scan end of May


Edited by gordon15 - May 10 2016 at 3:34pm
wife: IDC/Lobular Stage2B 2008 lumpectomy/TAC+rads
TNBC Stage 3A/w/metaplastic/squamous Nov2015 Carboplatin-Gemzar chemo/masectomy Taxolchemo+rads 4-16
PET scan stable 9-2016/ 1-2017
Back to Top
gordon15 View Drop Down
Senior Member
Senior Member


Joined: Jun 22 2015
Location: San Diego CA
Status: Offline
Points: 788
Post Options Post Options   Thanks (0) Thanks(0)   Quote gordon15 Quote  Post ReplyReply Direct Link To This Post Posted: May 10 2016 at 3:01pm
Here's a discussion from last year on carboplatin, your oncologist may have more recent info on platinum agents+Taxanes adjuvant chemo.

http://www.practiceupdate.com/content/controversy-continues-over-platinum-for-tnbc-patients/21743

Published in Oncology

News · February 08, 2015

Controversy Continues Over Platinum for TNBC Patients



  Dr. Eric P. Winer
  Dr. Andrew N.J. Tutt

SAN ANTONIO– Oncologists are split over the use of platinum compounds as adjuvant or neoadjuvant therapy for triple-negative breast cancer patients, a rift likely to continue until definitive outcome data become available several years from now.

“In the U.S., I would say that about half of all medical oncologists are now in a fairly routine manner giving carboplatin in this setting,” Dr. Eric P. Winer estimated at the San Antonio Breast Cancer Symposium.

He’s not among them.

“Is carboplatin ready for prime time use in the adjuvant or neoadjuvant setting in triple-negative breast cancer? I personally feel we first need a definitive study showing improvement in disease-free survival and/or overall survival, or something close to that,” said Dr. Winer, chief of the division of women’s cancers at the Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, Boston.

Proponents of platinum salts cite two positive phase II randomized trials – GeparSixto and CALGB 40603 – which demonstrated significantly higher pathologic complete response (pCR) rates in patients with stage II or III triple-negative breast cancer (TNBC) with the addition of carboplatin to neoadjuvant chemotherapy.

The pro-platinum camp points to evidence suggesting a pCR in women with TNBC appears to be a good surrogate endpoint for event-free survival and overall survival, as shown in a recent meta-analysis by Dr. Patricia Cortazar of the Food and Drug Administration and her coworkers. The investigators concluded that pCR in response to neoadjuvant therapy with various regimens was associated with a 76% improvement in event-free survival and an 84% improvement in overall survival in 557 women with TNBC (Lancet 2014;384:164-72).

“The two phase II studies are going in the same direction,” observed Dr. Gunter von Minckwitz of the German Breast Group and principal investigator in the GeparSixto trial. “We have surveyed our group of investigators, and they are all using platinum in triple-negative breast cancer. The German guidelines say you can, but you don’t have to.”

But Dr. Winer, and by his estimate roughly half of all American medical oncologists, remain unconvinced.

“I think we should all keep in mind that pCR is a marker of better outcome, it’s not necessarily a required step in the process,” he said.

He’s leery of relying upon pCR as a surrogate endpoint in light of the deeply disappointing BEATRICE experience. The phase III BEATRICE trial included nearly 2,600 women with TNBC who were randomized to adjuvant chemotherapy alone or in combination with bevacizumab. The bevacizumab group had a higher pCR, but no improvement in disease-free survival or overall survival (Lancet Oncol. 2013;14:933-42).

“I would hate to see us all indiscriminately adding platinum to standard regimens, increasing toxicity, particularly if it is not associated with long-term benefit,” Dr. Winer said. “And even if it is associated with long-term benefit, I want to tease out who really benefits and which triple-negative patients are most sensitive to these agents.”

Progress is occurring in this area, he added. In GeparSixto, the addition of neoadjuvant carboplatin to paclitaxel and nonpegylated liposomal doxorubicin was associated with a 66.7% pCR rate in the subgroup of TNBC patients with a BRCA 1 or 2 germline mutation and a 43.5% rate in those without such mutations (Lancet Oncol. 2014;15:747-56).

Moreover, in the phase III Triple Negative Breast Cancer Trial (TNT) presented at this year’s San Antonio symposium, Dr. Andrew N.J. Tutt reported that in a prespecified analysis of the small subgroup comprising 43 BRCA mutation-positive patients, the objective response rate was 68% in those randomized to carboplatin, compared with 33% in those assigned to docetaxel. Moreover, mean progression-free survival was 6.8 months with carboplatin, significantly better than the 4.8 months with docetaxel or the 3.1 months in carboplatin-treated patients without a BRCA 1/2 mutation.

The TNT trial included 376 patients with metastatic or recurrent locally advanced TNBC randomized to single agent therapy. While the study provides no evidence of a superior response to carboplatin, compared with docetaxel in unselected patients with metastatic TNBC, it does support BRCA 1/2 mutation genotyping as part of decision making regarding therapy in metastatic TNBC and familial breast cancer, according to Dr. Tutt, professor of breast oncology at the Institute of Cancer Research, London.

The trial also tested the utility of Myriad Genetics’ novel Homologous Recombination Deficiency (HRD) score as a predictor of platinum-responsiveness of TNBC and concluded it was without benefit.

Dr. Winer noted that TNBC accounts for only about 15% of breast cancers. Still, that’s roughly 35,000 new cases per year in the United States alone – and TNBC is responsible for a disproportionate degree of breast cancer mortality.

“Perhaps in patients with BRCA 1 or 2 mutations, we’re getting close to thinking that platinum may be a standard, but even here I would await the completion of ongoing trials before we embrace that concept,” he said.

Among these studies is the 12-258 INFORM trial, a multicenter study in which 166 newly diagnosed breast cancer patients with BRCA1 or 2 mutations are being randomized to preoperative cisplatin or doxorubicin/cyclophosphamide.

Dr. William M. Sikov, principal investigator for the CALGB 40603 trial (J. Clin. Oncol. 2015;33:13-21), predicted there will be little crossover between the platinum-user and nonuser camps until definitive trials report whether the therapy improves relapse-free or overall survival.

“One group will say, ‘There’s an absolute increase in pathologic complete response with carboplatin in these two studies, and I’m convinced it’s a beneficial drug in these patients.’ It’s inexpensive, it’s available, although not approved for triple negative breast cancer, and it has some hematologic toxicities. But we have no long-term outcomes yet. I don’t think the TNT results will change anyone’s mind,” according to Dr. Sikov of Women and Infants Hospital in Providence, R.I.

Dr. Winer reported receiving research funding from Genentech. Dr. Sikov serves as a consultant to AbbVie and Celgene. Dr. Tutt reported having no financial conflicts.




Edited by gordon15 - May 10 2016 at 3:03pm
wife: IDC/Lobular Stage2B 2008 lumpectomy/TAC+rads
TNBC Stage 3A/w/metaplastic/squamous Nov2015 Carboplatin-Gemzar chemo/masectomy Taxolchemo+rads 4-16
PET scan stable 9-2016/ 1-2017
Back to Top
mkcrowe View Drop Down
Newbie
Newbie
Avatar

Joined: Apr 27 2016
Location: San Francisco
Status: Offline
Points: 11
Post Options Post Options   Thanks (1) Thanks(1)   Quote mkcrowe Quote  Post ReplyReply Direct Link To This Post Posted: May 10 2016 at 6:20pm
Wow, Gordon. This is so helpful. I really appreciate it. Such good news to hear about your wife, and I am keeping my fingers tightly crossed for your results at the end of May. 

Thanks again, and best of luck to us all. 

Kelsey 


Back to Top
gordon15 View Drop Down
Senior Member
Senior Member


Joined: Jun 22 2015
Location: San Diego CA
Status: Offline
Points: 788
Post Options Post Options   Thanks (0) Thanks(0)   Quote gordon15 Quote  Post ReplyReply Direct Link To This Post Posted: May 10 2016 at 8:07pm
Thanks for your reply, I have no idea if Carboplatin/Gemzar worked on my wife, but it killed the small mets in the lymph nodes, and 75% of her tumor as an neoadjuvant (chemo before surgery) but maybe Donna has more recent statistics on if the platinum
From everything I have read, Carbo/Gem seems to have an edge if administered before surgery (neoadjuvant chemo)especially for BRCA +(positive) genes detected... doctors seem to be assessing it's effectiveness after surgery, but they seem to be split 50/50 on this course of action, again, this is my total assumption, after reading what I can find.

The doctors are equally concerned about toxicity,for administering platinum agents...

http://www.practiceupdate.com/content/controversy-continues-over-platinum-for-tnbc-patients/21743





Edited by gordon15 - May 10 2016 at 8:35pm
wife: IDC/Lobular Stage2B 2008 lumpectomy/TAC+rads
TNBC Stage 3A/w/metaplastic/squamous Nov2015 Carboplatin-Gemzar chemo/masectomy Taxolchemo+rads 4-16
PET scan stable 9-2016/ 1-2017
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 12.01
Copyright ©2001-2018 Web Wiz Ltd.